Members of the Communist Party faction in the Legislative Assembly proposed to organize an irreducible stock of drugs in pharmacies in the Nizhny Novgorod region. This was reported by the press service of the regional branch of the party.
According to the communists, such measures will help to protect the residents of the region during a pandemic and seasonal respiratory diseases.
On December 25, 2020, a draft resolution on the appeal of ZSNO to Mikhail Mishustin was submitted to the regional parliament for consideration. It says the coronavirus has demonstrated shortcomings in the healthcare and drug supply system in Russia. In particular, the subjects faced drug shortages.
At the same time, WHO experts do not deny that COVID-19 can become a seasonal disease, like the flu. At the same time, prices for medicines jumped this year, in some cases the growth exceeded 70% compared to the same period in 2019.
Prices for drugs coronavir, areplivir and their analogues (retail cost exceeds 5 thousand rubles, and for a course of 11 thousand rubles), make them inaccessible to citizens of retirement age, especially against the background of decreasing purchasing power of Russian citizens and inflationary economic processes, - it is noted in the circulation of the Communist Party faction.
At the end of the year, the prosecutor's office of the Nizhny Novgorod region checked more than 180 pharmacies for the availability of drugs. It turned out that many of them did not have antiviral, antipyretic and mucolytic drugs included in the list of vital and essential drugs. A similar thing was noticed in 40 municipalities of the region.
The Communists believe that it is necessary to consolidate in this article the obligation of pharmacy organizations to provide a minimum two-month supply of medicines. It is also worth expanding the list of drugs approved by the government, supplementing it with drugs for the treatment of COVID-19, as well as a large number of drugs for the treatment of other viral respiratory diseases.
It was also proposed to monitor drug price movements at the federal level.